Folosim cookie-uri pentru a îmbunătăți experiența pe site. Pentru detalii, citește Politica de confidențialitate.

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

10.04.2026 22:55 | The Guardian World

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant casesA drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing. Continue reading...

🔗 Citește articolul complet pe The Guardian World